Tocilizumab Dosing Regimen Recommendations
The recommended tocilizumab dosing regimen is 8 mg/kg intravenously over 1 hour (not to exceed 800 mg per dose), which can be repeated every 8 hours if no improvement is observed, with a maximum of 3 doses in 24 hours and 4 doses total. 1, 2
Dosing Based on Clinical Indication
For Cytokine Release Syndrome (CRS)
Grade 1 CRS (fever ≥38°C):
Grade 2 CRS (fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen):
Grade 3-4 CRS:
For Rheumatoid Arthritis
- Intravenous administration: 8 mg/kg every 4 weeks 3, 4
- Subcutaneous administration: 162 mg weekly or every other week (depending on weight) 3
For Giant Cell Arteritis
For Steroid-Refractory Acute Graft-versus-Host Disease
- 8 mg/kg IV every 2-4 weeks 5
- More frequent dosing (every 2 weeks) appears to yield better results than every 3-4 weeks 5
Pharmacokinetic Considerations
Half-life varies by indication and administration route:
Body weight considerations:
- Higher exposure in patients with lower body weight
- For SC dosing in GCA patients <60 kg, steady-state concentration is 51% higher (weekly dosing) or 129% higher (every other week dosing) compared to patients 60-100 kg 3
Monitoring Requirements
- Complete blood count (CBC) and liver function tests (LFTs):
- Within first 1-2 months of usage
- Every 3-4 months thereafter 6
- Lipid levels: Every 6 months 6
- Dose adjustment recommendations for abnormal LFTs:
- If 1-3 times ULN: Decrease dose or increase interval between doses
- If >3 times ULN: Withhold administration
- If >5 times ULN: Discontinue treatment 6
Important Safety Considerations
- Infection risk: Monitor for signs of infection, particularly in neutropenic patients 1, 2
- Hematologic effects: Monitor for neutropenia, thrombocytopenia, and anemia 3, 7
- Lipid abnormalities: Significant increases in total, HDL, LDL cholesterol, and triglycerides 7
- Hepatotoxicity: Do not initiate in patients with elevated LFTs (>1.5 times ULN) 6
- Rare complications: Cases of accelerated subcutaneous nodulosis have been reported 8
Special Populations
- COVID-19 patients: Under FDA Emergency Use Authorization, limit to maximum of 2 doses during a CRS episode and consider more aggressive steroid use 1
- Pediatric patients: Different dosing based on body weight categories and indication 3
- Elderly: Consider one dose for Grade 1 CRS due to comorbidities 1
Remember that tocilizumab availability may be limited due to FDA Emergency Use Authorization for COVID-19 patients, which may necessitate alternative approaches such as earlier or more aggressive steroid use or consideration of alternative agents like siltuximab or anakinra 1.